West Pharmaceutical Services Inc (WST) Stock Analysis and Metrics

West Pharmaceutical Services

NYSE: WST

$328.12 ▼ -27.36 (-7.70%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap23.80 Bn

P/E45.05

P/S7.39

Div. Yield0.00

Total Debt (Qtr)202.80 Mn

Revenue Growth (1y) (Qtr)21.05

Add ratio to table…

About

West Pharmaceutical Services Inc is a leading global manufacturer that designs and produces technologically advanced containment and delivery systems for injectable drugs and healthcare products. The company focuses on primary proprietary packaging solutions such as stoppers seals syringe and cartridge components as well as drug delivery devices integrated systems and analytical lab services. It also provides contract manufacturing and integrated solutions that combine packaging components with device assembly and technical support. West Pharmaceutical Services Inc serves biologic generic pharmaceutical diagnostic and medical device companies worldwide. Its core mission is to deliver quality products that meet exact customer specifications while enabling safe and effective drug delivery to patients.

The company generates revenue primarily through the sale of its proprietary products and contract manufactured products. Proprietary products include elastomer based containment components drug delivery devices integrated systems and analytical lab services that are sold to drug manufacturers for use in their injectable formulations. Contract manufactured products consist of custom designed and assembled devices such as surgical diagnostic ophthalmic and drug delivery systems that are produced for pharmaceutical diagnostic and medical device customers. Revenue is also derived from related services such as analytical testing pre approval packaging support engineering development regulatory expertise and after sales technical support. The firm sells its offerings mainly through its own sales force and distribution network with limited reliance on third party agents. A significant portion of sales comes from international markets with sales outside the United States representing more than half of consolidated net sales.

The company operates through the following segments: Proprietary Products and Contract Manufactured Products.

• The Proprietary Products segment offers elastomers and primary containment solutions drug delivery devices integrated systems and analytical lab services primarily to biologic generic and pharmaceutical drug customers. Its packaging products include stoppers and seals for injectable packaging systems that help ensure drug compatibility and stability while supporting customer operational efficiency. The segment also provides syringe and cartridge components including custom solutions for specific injectable drug applications as well as administration systems that enhance safe drug delivery through advanced reconstitution mixing and transfer technologies. Additional offerings comprise films coatings washing vision inspection and sterilization processes that improve packaging quality and reduce contamination risk. The segment’s product portfolio further includes drug containment solutions such as vials syringes plungers and cartridges that address glass incompatibility and perform well in cold storage environments. It also supplies self injection devices designed for at home delivery of injectable therapies and provides integrated solutions that combine primary packaging containment and drug delivery devices with analytical lab services pre approval support engineering development regulatory expertise and after sales technical support. Manufacturing facilities for this segment are located in North and South America Europe and Asia with affiliated companies in Japan and Mexico.

• The Contract Manufactured Products segment serves as a fully integrated business focused on the design manufacture and automated assembly of complex devices primarily for pharmaceutical diagnostic and medical device customers. These products include custom contract manufacturing and assembly solutions that use technologies such as multi component molding in mold labeling ultrasonic welding clean room molding device assembly and drug handling capabilities. The segment manufactures customer owned components and devices used in surgical diagnostic ophthalmic injectable and other drug delivery systems as well as consumer products. It has extensive expertise in product design and development including in house mold design process design and validation and high speed automated assemblies. Manufacturing facilities for this segment are located in North America and Europe.

West Pharmaceutical Services Inc holds a strong position in the global market for injectable drug containment and delivery systems. The company competes with firms such as Datwyler and Aptar in the proprietary packaging space where competition centers on product design performance quality regulatory compliance scientific expertise and total cost. It also faces competition from numerous suppliers of medical devices and device components including pharmaceutical manufacturers that may become customers of its drug delivery products. West differentiates itself through its reputation for quality and reliability in engineering and project management and its deep knowledge of regulatory requirements. Its specialized expertise in container closure components supports the development of effective delivery systems. The firm leverages its range of proprietary technologies to compete with both new and established players in drug delivery devices such as suppliers of prefillable syringes auto injectors safety needles and other proprietary systems. West emphasizes its role as a global supplier of integrated drug containment and delivery systems offering pre approval primary packaging support engineering development analytical lab services integrated solutions regulatory expertise and after sale technical support. Customers value its worldwide manufacturing footprint and its ability to produce products at multiple sites. In the contract manufactured products arena the company contends with smaller regional players like SMC Ltd and large global assembly manufacturers such as Phillips Medisize. To stand out West relies on its global capabilities brand reputation and the use of advanced technologies including high speed automated assembly insert molding multi shot precision molding expertise with multiple piece closure systems and scalable drug packaging and assembly solutions which broaden its competitive set to include contract manufacturing organizations such as Sharp and PCI Pharma Services.

West Pharmaceutical Services Inc serves a diverse customer base that includes leading biologic generic pharmaceutical diagnostic and medical device companies worldwide. Its Proprietary Products are purchased by major biologic generic and pharmaceutical drug manufacturers that integrate the company’s components into their injectable formulations for delivery to patients. The Contract Manufactured Products segment supplies many of the world’s largest pharmaceutical diagnostic and medical device firms that use its custom assembled devices in their production lines. The company distributes its offerings mainly through its own sales force and distribution network with only limited reliance on third party agents. In 2025 the ten largest customers represented approximately 47.6 percent of consolidated net sales with a single customer contributing about 15.8 percent of sales. This concentration highlights the importance of key relationships while the broad customer mix provides stability across the firm’s product lines.

Investment Thesis

▲ Bull case

WST’s management has positioned the company to capitalize on the accelerating adoption of GLP-1 therapies beyond diabetes and obesity, with explicit confirmation from the CEO that early signs of new indications and deeper penetration of both oral and injectable forms are already emerging. This is significant because GLP-1 drugs are expanding into cardiovascular, renal, and neurodegenerative indications, which could dramatically increase the addressable market for injectable delivery systems. The company’s high-value components like NovaPure and Crystal Zenith are specifically engineered for these complex biologics, creating a durable moat that competitors cannot easily replicate. The fact that management cited expanding insurance coverage, FDA actions on compounded drugs, and upcoming generic launches outside the U.S. as growth drivers suggests a multi-year tailwind that is still in its early innings, with the potential to sustain double-digit growth in this segment well beyond 2026.
The company’s operational excellence initiative, which accelerated onboarding, enabled multi-site qualifications, and transferred best practices across its global manufacturing network, is delivering tangible results that are not fully reflected in current guidance. Management confirmed that these efforts increased throughput and capacity without requiring new capital expenditures, and CFO Robert McMahon explicitly stated that some of these improvements were baked into the raised full-year guidance. This means WST is extracting more value from its existing asset base—particularly in high-margin HVP components—through process optimization rather than just volume growth. The ability to improve margins via operational leverage, especially in Europe where the initiative was first tested, suggests a sustainable path to margin expansion that could exceed the 50 basis points of additional improvement hinted at for the full year, providing upside to earnings that is not yet priced in.
WST’s strategic pivot toward higher-margin drug handling and delivery solutions through the West Vantage segment is being underestimated by the market, despite management’s clear articulation that this business has a gross margin “well at least twice as much” as legacy contract manufacturing. The Dublin facility is now fully operational and positioned to capture growth from high-volume injectable therapies in diabetes and obesity, with the CFO noting that the drug handling business could reach 3x its current $20 million run rate by 2027. This represents a structural shift in the company’s mix toward higher-margin, less capital-intensive revenue streams, which is being masked by the near-term drag from the CGM contract roll-off. As this transition progresses, West Vantage could become a meaningful contributor to both revenue and margin expansion, offering a hidden catalyst that investors are overlooking due to short-term noise.
The company’s international expansion, particularly in Asia Pacific where organic growth reached 29% in Q1, is being driven by structural demand from CDMOs and biotech firms seeking to access Western markets—a trend that is not merely cyclical but reflects a deeper globalization of biologics development. Management highlighted this as a key growth lever, noting that the region supports both local consumption and export-oriented manufacturing, with increasing engagement from emerging biotechs. This geographic diversification reduces reliance on any single market and provides a runway for sustained growth that is less susceptible to regional economic fluctuations, offering a multi-year advantage that is not yet fully appreciated in current valuations.
WST’s identification of at least 6 billion units targeted for conversion under Annex 1 regulatory upgrades represents a multi-decade opportunity that is still in its earliest stages, with management emphasizing they are “early innings” in this initiative. The fact that customers are now making global standardization decisions—extending beyond Europe to the U.S. and Asia—means the potential for this tailwind is being underestimated. The company’s ability to leverage its existing HVP finishing processes to convert standard products into higher-margin components creates a self-reinforcing cycle: as more customers adopt these upgrades, volume increases, margins improve, and capacity utilization rises, all without requiring proportional increases in capex. This structural shift in product mix is a durable source of growth that could deliver consistent mid-single-digit annual contributions to revenue for years to come.

WST’s management has positioned the company to capitalize on the accelerating adoption of GLP-1 therapies beyond diabetes and obesity, with explicit confirmation from the CEO that early signs of new indications and deeper penetration of both oral and injectable forms are already emerging. This is significant because GLP-1 drugs are expanding into cardiovascular, renal, and neurodegenerative indications, which could dramatically increase the addressable market for injectable delivery systems. The company’s high-value components like NovaPure and Crystal Zenith are specifically engineered for these complex biologics, creating a durable moat that competitors cannot easily replicate. The fact that management cited expanding insurance coverage, FDA actions on compounded drugs, and upcoming generic launches outside the U.S. as growth drivers suggests a multi-year tailwind that is still in its early innings, with the potential to sustain double-digit growth in this segment well beyond 2026.
The company’s operational excellence initiative, which accelerated onboarding, enabled multi-site qualifications, and transferred best practices across its global manufacturing network, is delivering tangible results that are not fully reflected in current guidance. Management confirmed that these efforts increased throughput and capacity without requiring new capital expenditures, and CFO Robert McMahon explicitly stated that some of these improvements were baked into the raised full-year guidance. This means WST is extracting more value from its existing asset base—particularly in high-margin HVP components—through process optimization rather than just volume growth. The ability to improve margins via operational leverage, especially in Europe where the initiative was first tested, suggests a sustainable path to margin expansion that could exceed the 50 basis points of additional improvement hinted at for the full year, providing upside to earnings that is not yet priced in.
WST’s strategic pivot toward higher-margin drug handling and delivery solutions through the West Vantage segment is being underestimated by the market, despite management’s clear articulation that this business has a gross margin “well at least twice as much” as legacy contract manufacturing. The Dublin facility is now fully operational and positioned to capture growth from high-volume injectable therapies in diabetes and obesity, with the CFO noting that the drug handling business could reach 3x its current $20 million run rate by 2027. This represents a structural shift in the company’s mix toward higher-margin, less capital-intensive revenue streams, which is being masked by the near-term drag from the CGM contract roll-off. As this transition progresses, West Vantage could become a meaningful contributor to both revenue and margin expansion, offering a hidden catalyst that investors are overlooking due to short-term noise.
The company’s international expansion, particularly in Asia Pacific where organic growth reached 29% in Q1, is being driven by structural demand from CDMOs and biotech firms seeking to access Western markets—a trend that is not merely cyclical but reflects a deeper globalization of biologics development. Management highlighted this as a key growth lever, noting that the region supports both local consumption and export-oriented manufacturing, with increasing engagement from emerging biotechs. This geographic diversification reduces reliance on any single market and provides a runway for sustained growth that is less susceptible to regional economic fluctuations, offering a multi-year advantage that is not yet fully appreciated in current valuations.
WST’s identification of at least 6 billion units targeted for conversion under Annex 1 regulatory upgrades represents a multi-decade opportunity that is still in its earliest stages, with management emphasizing they are “early innings” in this initiative. The fact that customers are now making global standardization decisions—extending beyond Europe to the U.S. and Asia—means the potential for this tailwind is being underestimated. The company’s ability to leverage its existing HVP finishing processes to convert standard products into higher-margin components creates a self-reinforcing cycle: as more customers adopt these upgrades, volume increases, margins improve, and capacity utilization rises, all without requiring proportional increases in capex. This structural shift in product mix is a durable source of growth that could deliver consistent mid-single-digit annual contributions to revenue for years to come.

▼ Bear case

WST’s guidance assumes that the CGM contract roll-off will create a $40 million revenue headwind in the second half of 2026, yet management has not provided sufficient detail on whether this impact is fully offset by new wins in the West Vantage segment, particularly in drug handling. While the CFO noted the drug handling business could reach 3x its current $20 million run rate by 2027, this implies only $60 million in annual revenue by then—leaving a significant gap in the near term. The lack of clarity on the timing and scale of replacement revenue raises concerns that the transition may not be as seamless as suggested, potentially leaving a persistent drag on growth that could undermine the full-year guidance, especially if customer conversions in the West Vantage segment proceed more slowly than anticipated due to qualification timelines or competitive pressures.
Despite management’s optimism about GLP-1 expansion into new indications, the company remains heavily reliant on the continued success of injectable semaglutide and tirzepatide, with GLP-1 contributing exactly 10% of total sales for the second straight quarter. Any slowdown in the adoption of injectable GLP-1 therapies—whether due to efficacy concerns, side effects, or faster-than-expected uptake of oral alternatives—could disproportionately impact WST’s highest-margin business. The fact that oral GLP-1s are already expanding the market, as noted by the CEO, introduces a tangible risk that the company’s core HVP components business may face headwinds if patients and providers shift toward non-injectable formulations, a dynamic that is not yet fully reflected in their growth assumptions.
The company’s operational excellence initiative, while yielding benefits in Q1, may not be sustainable at the same pace throughout the year, particularly as the initial benefits from redeploying European team members and accelerated onboarding begin to normalize. Management acknowledged that the margin expansion seen in Q1 was partly driven by temporary workforce reallocation, and there is no clear evidence that these efficiency gains will persist without ongoing investment or further structural changes. If the benefits are transient, the implied margin expansion for the full year—already modest at 50 basis points of additional improvement—may not materialize, leaving the company more vulnerable to rising input costs than currently projected.
WST’s exposure to geopolitical and macroeconomic risks, while downplayed in the call, remains a latent threat given the concentration of its manufacturing footprint in Europe (which accounted for 17.9% organic growth in Q1) and the ongoing vulnerabilities exposed by the cyberattack. The incident disrupted logistics and manufacturing globally, and while systems were restored, the lack of transparency around the financial impact or timeline for full resilience raises questions about the robustness of its IT infrastructure and supply chain security. In an era of increasing cyber threats to industrial firms, the potential for repeat incidents—especially if defenses are not sufficiently strengthened—could lead to recurring operational disruptions that erode margins and undermine investor confidence in the company’s operational stability.
The company’s reliance on customer-driven multi-site qualification as a lever for capacity expansion introduces execution risk, as the process takes 6 to 12 months per site and depends heavily on customer cooperation. If key clients delay or fail to complete qualification due to internal bottlenecks, regulatory hurdles, or shifting priorities, the anticipated load balancing and throughput gains may not materialize as expected. This dependency creates a vulnerability where WST’s ability to scale output is constrained not by its own capital investment but by the pace of external validation, which could slow the realization of benefits from its operational excellence program and limit upside to revenue growth in later quarters.

WST’s guidance assumes that the CGM contract roll-off will create a $40 million revenue headwind in the second half of 2026, yet management has not provided sufficient detail on whether this impact is fully offset by new wins in the West Vantage segment, particularly in drug handling. While the CFO noted the drug handling business could reach 3x its current $20 million run rate by 2027, this implies only $60 million in annual revenue by then—leaving a significant gap in the near term. The lack of clarity on the timing and scale of replacement revenue raises concerns that the transition may not be as seamless as suggested, potentially leaving a persistent drag on growth that could undermine the full-year guidance, especially if customer conversions in the West Vantage segment proceed more slowly than anticipated due to qualification timelines or competitive pressures.
Despite management’s optimism about GLP-1 expansion into new indications, the company remains heavily reliant on the continued success of injectable semaglutide and tirzepatide, with GLP-1 contributing exactly 10% of total sales for the second straight quarter. Any slowdown in the adoption of injectable GLP-1 therapies—whether due to efficacy concerns, side effects, or faster-than-expected uptake of oral alternatives—could disproportionately impact WST’s highest-margin business. The fact that oral GLP-1s are already expanding the market, as noted by the CEO, introduces a tangible risk that the company’s core HVP components business may face headwinds if patients and providers shift toward non-injectable formulations, a dynamic that is not yet fully reflected in their growth assumptions.
The company’s operational excellence initiative, while yielding benefits in Q1, may not be sustainable at the same pace throughout the year, particularly as the initial benefits from redeploying European team members and accelerated onboarding begin to normalize. Management acknowledged that the margin expansion seen in Q1 was partly driven by temporary workforce reallocation, and there is no clear evidence that these efficiency gains will persist without ongoing investment or further structural changes. If the benefits are transient, the implied margin expansion for the full year—already modest at 50 basis points of additional improvement—may not materialize, leaving the company more vulnerable to rising input costs than currently projected.
WST’s exposure to geopolitical and macroeconomic risks, while downplayed in the call, remains a latent threat given the concentration of its manufacturing footprint in Europe (which accounted for 17.9% organic growth in Q1) and the ongoing vulnerabilities exposed by the cyberattack. The incident disrupted logistics and manufacturing globally, and while systems were restored, the lack of transparency around the financial impact or timeline for full resilience raises questions about the robustness of its IT infrastructure and supply chain security. In an era of increasing cyber threats to industrial firms, the potential for repeat incidents—especially if defenses are not sufficiently strengthened—could lead to recurring operational disruptions that erode margins and undermine investor confidence in the company’s operational stability.
The company’s reliance on customer-driven multi-site qualification as a lever for capacity expansion introduces execution risk, as the process takes 6 to 12 months per site and depends heavily on customer cooperation. If key clients delay or fail to complete qualification due to internal bottlenecks, regulatory hurdles, or shifting priorities, the anticipated load balancing and throughput gains may not materialize as expected. This dependency creates a vulnerability where WST’s ability to scale output is constrained not by its own capital investment but by the pace of external validation, which could slow the realization of benefits from its operational excellence program and limit upside to revenue growth in later quarters.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password